PrEP Access and Coverage Act

Summary#

This bill, the PrEP Access and Coverage Act of 2026, would require broad health coverage and remove several barriers to pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP) for HIV. Its main change is to make FDA‑approved PrEP/PEP drugs and the related tests and follow-up care covered without patient cost-sharing by many public and private programs. The bill also funds education and grants, protects confidentiality, and bans insurance discrimination for people taking PrEP.

• Private plans would have to cover PrEP drugs, lab tests, and follow-up care without cost-sharing as a preventive service and mostly without preauthorization (prior approval).
• Medicaid, CHIP, Medicare, FEHB, VA, DoD, and Indian Health Service programs would be required to cover PrEP/PEP and eliminate related copayments or cost-sharing.
• Grants and education: HHS must set up grant programs for states, tribes, and nonprofit clinics and run public and provider education campaigns about PrEP/PEP.
• Confidentiality changes would let someone use PrEP benefits on a family plan without notifying other people on that plan.
• Insurance discrimination ban: Life, disability, and long‑term care insurers could not deny coverage or raise premiums just because someone takes PrEP.
• Enforcement and reporting: Agencies must issue guidance, collect annual compliance data from insurers, and report to Congress regularly.

What it means for you#

• People at risk of HIV

  • PrEP and PEP drugs, the required lab tests, and clinical follow-up would be covered without copays or coinsurance under most private and public plans named in the bill.
  • You could access PrEP under a family insurance plan without the primary policyholder being automatically informed (the bill directs HHS to change HIPAA rule-making to allow this confidentiality).
  • You could sue if a plan or insurer violates the law (private right of action).

• People on Medicaid or CHIP

  • States must include HIV prevention services in Medicaid and CHIP coverage and not charge cost-sharing for them. Effective date rules apply; states that need to change law get extra time.

• Medicare beneficiaries

  • Medicare Part B would cover HIV prevention services and remove coinsurance and Part B deductible for specific prevention drugs starting January 1, 2027.
  • Medicare Part D would eliminate deductibles and other cost-sharing for PrEP drugs starting January 1, 2027.

• Veterans and military beneficiaries

  • VA and TRICARE (military health) would provide PrEP/PEP without medication copayments or other cost-sharing.

• People using Indian Health Service

  • IHS would be funded to provide PrEP/PEP drugs, tests, and follow-up. The bill authorizes "such sums as are necessary" (no dollar amount given).

• Health care providers and clinics

  • More patients may seek PrEP/PEP. The bill funds provider education and grants that clinics can apply for to expand services and navigation support.

• Private insurers and employers

  • Must cover PrEP/PEP as preventive services without cost-sharing and usually cannot require prior authorization for those services. They must submit annual compliance data to HHS for 10 years.
  • Life, disability, and long‑term care insurers cannot use PrEP use as a reason to deny or surcharge coverage.

• States and grant applicants

  • States, territories, tribes, and qualifying nonprofits can apply for federal grants to run PrEP/PEP programs. Grant awards consider local need and uninsured populations.

Expenses#

Estimated public cost: No dollar estimates are provided in the bill text.

• The bill repeatedly authorizes appropriations by saying “such sums as may be necessary” for:
  • IHS PrEP/PEP funding,
  • the CDC public and provider education campaigns (fiscal years 2026–2030),
  • grants to states, tribes, and nonprofit entities (fiscal years 2026–2030).
• Medicare cost-sharing elimination for Part B and Part D drugs could increase federal spending, but the bill gives no cost estimate.
• Medicaid and CHIP coverage requirements could change federal/state spending and administration, but no fiscal estimate is provided.
• Administrative and compliance costs: HHS, Labor, and Treasury must monitor compliance, issue guidance, and collect annual insurer data for 10 years. Insurers and plans must submit data annually and implement coverage and reporting changes. No cost figures are given.
• Private insurers may lose cost-sharing revenue for PrEP/PEP drugs and services; the bill does not estimate offsetting effects on premiums.

No publicly available information on total budget impact is contained in the bill text.

Proponents' View#

The bill appears intended to increase PrEP and PEP access and reduce new HIV infections and disparities in care. Possible reasons someone would support the bill include:

• It could lower financial barriers by removing copays and deductibles for prevention drugs and related care.
• It would remove prior‑authorization hurdles that can delay access to medication.
• It could expand access across many public programs (Medicaid, Medicare, VA, DoD, IHS, FEHB) and private plans, making coverage more uniform.
• Grants and education campaigns could increase awareness and provider readiness, especially in communities with low PrEP/PEP use.
• Confidentiality protections aim to reduce privacy barriers for people on family plans.
• The ban on using PrEP use to deny or charge more for life/disability/LTC insurance removes a potential source of discrimination.

Opponents' View#

The bill’s text raises several possible concerns or trade-offs:

• The bill does not provide cost estimates, so the federal and state budget impacts are unclear. Eliminating Medicare and other cost-sharing could increase federal spending.
• States may face administrative or fiscal effects for implementing Medicaid/CHIP changes; the bill allows extra time only if state law changes are needed.
• Insurers and employers may face higher drug and service costs and compliance burdens from coverage and reporting requirements; this could affect premiums or plan design elsewhere.
• The exception allowing preauthorization when a therapeutically equivalent drug is available may be complex in practice and could create disputes about equivalence or access to specific formulations.
• The bill repeatedly authorizes “such sums as may be necessary” without specific appropriations, leaving uncertain how much funding will actually be provided for grants, IHS services, and education campaigns.
• Enforcement depends on agencies issuing guidance and monitoring compliance; practical enforcement details and timelines are not fully specified.
• The private right of action could increase litigation against plans and insurers; the bill does not quantify likely legal costs.

What is unclear: The bill does not include fiscal notes or dollar authorizations. It also does not detail how HHS will operationalize confidentiality changes under HIPAA, or how therapeutic equivalence exceptions to the no‑preauthorization rule will be applied.